Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based Inhibitors
Viviana De Luca, Andrea Angeli, Alessio Nocentini, Paola Gratteri, Silvia Pratesi, Damiano Tanini, Vincenzo Carginale, Antonella Capperucci, Claudiu T Supuran, Clemente Capasso
International Journal of Molecular Sciences, doi:10.3390/ijms25020971
The implementation of innovative approaches is crucial in an ongoing endeavor to mitigate the impact of COVID-19 pandemic. The present study examines the strategic application of the SARS-CoV-2 Main Protease (M pro ) as a prospective instrument in the repertoire to combat the virus. The cloning, expression, and purification of M pro , which plays a critical role in the viral life cycle, through heterologous expression in Escherichia coli in a completely soluble form produced an active enzyme. The hydrolysis of a specific substrate peptide comprising a six-amino-acid sequence (TSAVLQ) linked to a p-nitroaniline (pNA) fragment together with the use of a fluorogenic substrate allowed us to determine effective inhibitors incorporating selenium moieties, such as benzoselenoates and carbamoselenoates. The new inhibitors revealed their potential to proficiently inhibit M pro with IC 50 -s in the low micromolar range. Our study contributes to the development of a new class of protease inhibitors targeting M pro , ultimately strengthening the antiviral arsenal against COVID-19 and possibly, related coronaviruses.
Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/ijms25020971/s1.
Conflicts of Interest: The authors declare no conflicts of interest.
References
Ali, Benedetti, Handzlik, Zwergel, Battistelli, The innovative potential of seleniumcontaining agents for fighting cancer and viral infections, Drug Discov. Today,
doi:10.1016/j.drudis.2020.10.014Amporndanai, Meng, Shang, Jin, Rogers et al., Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives, Nat. Commun,
doi:10.1038/s41467-021-23313-7Angeli, Carta, Donnini, Capperucci, Ferraroni et al., Selenolesterase enzyme activity of carbonic anhydrases, Chem. Commun,
doi:10.1039/D0CC00995DAngeli, Ferraroni, Capperucci, Tanini, Costantino et al., Selenocarbamates As a Prodrug-Based Approach to Carbonic Anhydrase Inhibition, ChemMedChem,
doi:10.1002/cmdc.202200085Angeli, Tanini, Nocentini, Capperucci, Ferraroni et al., A new class of carbonic anhydrase inhibitors, Chem. Commun,
doi:10.1039/C8CC08562EBhardwaj, Singh, Das, Purohit, Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs, Comput. Biol. Med,
doi:10.1016/j.compbiomed.2020.104117Buxeraud, Faure, Fougere, Nirmatrelvir/ritonavir (Paxlovid(R)), a treatment for COVID-19, Actual. Pharm
Cao, Goreshnik, Coventry, Case, Miller et al., De novo design of picomolar SARS-CoV-2 miniprotein inhibitors, Science,
doi:10.1126/science.abd9909Capasso, Nocentini, Supuran, Protease inhibitors targeting the main protease and papain-like protease of coronaviruses, Expert Opin. Ther. Pat,
doi:10.1080/13543776.2021.1857726Capperucci, Petrucci, Faggi, Tanini, Click Reaction of Selenols with Isocyanates: Rapid Access to Selenocarbamates as Peroxide-Switchable Reservoir of Thiol-peroxidase-Like Catalysts, Adv. Synth. Catal,
doi:10.1002/adsc.202100611Carabelli, Peacock, Thorne, Harvey, Hughes et al., SARS-CoV-2 variant biology: Immune escape, transmission and fitness, Nat. Rev. Microbiol,
doi:10.1038/s41579-022-00841-7Chavda, Vuppu, Mishra, Kamaraj, Patel et al., Recent review of COVID-19 management: Diagnosis, treatment and vaccination, Pharmacol. Rep,
doi:10.1007/s43440-022-00425-5Chen, Shao, Peng, Liang, Xu et al., Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection, Front. Pharmacol,
doi:10.3389/fphar.2022.1035969Citarella, Scala, Piperno, Micale, SARS-CoV-2 M pro : A Potential Target for Peptidomimetics and Small-Molecule Inhibitors, Biomolecules,
doi:10.3390/biom11040607Da Silva, Do Nascimento, Mendes, Guarines, Da Silva et al., Two Years into the COVID-19 Pandemic: Lessons Learned, ACS Infect. Dis,
doi:10.1021/acsinfecdis.2c00204Deniz, Uysal, Capasso, Supuran, Ozensoy Guler, Is carbonic anhydrase inhibition useful as a complementary therapy of COVID-19 infection?, J. Enzym. Inhib. Med. Chem,
doi:10.1080/14756366.2021.1924165Elnaggar, Elgazar, Gamal, Hamed, Elsayed et al., Identification of sulphonamide-tethered N-((triazol-4-yl)methyl)isatin derivatives as inhibitors of SARS-CoV-2 main protease, J. Enzym. Inhib. Med. Chem,
doi:10.1080/14756366.2023.2234665Eltayb, Abdalla, Rabie, Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir "S-217622": A Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species, ACS Omega,
doi:10.1021/acsomega.2c03881Flynn, Samant, Schneider-Nachum, Barkan, Yilmaz et al., Comprehensive fitness landscape of SARS-CoV-2 M pro reveals insights into viral resistance mechanisms, eLife,
doi:10.7554/eLife.77433Ghosh, Mishevich, Mesecar, Mitsuya, Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19, ChemMedChem,
doi:10.1002/cmdc.202200440Hashemian, Sheida, Taghizadieh, Memar, Hamblin et al., Nirmatrelvir/Ritonavir): A new approach to COVID-19 therapy?, Biomed. Pharmacother,
doi:10.1016/j.biopha.2023.114367Hoffman, Kania, Brothers, Davies, Ferre et al., Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19, J. Med. Chem,
doi:10.1021/acs.jmedchem.0c01063Hou, Dong, Zhang, Wang, Su et al., Selenium as an emerging versatile player in heterocycles and natural products modification, Drug Discov. Today,
doi:10.1016/j.drudis.2022.03.020Hu, Xiong, Zhu, Zhang, Zhang et al., The SARS-CoV-2 main protease (M pro ): Structure, function, and emerging therapies for COVID-19, MedComm,
doi:10.1002/mco2.151Iacobucci, COVID-19: Evusheld protects the most vulnerable patients, analysis shows, BMJ-Br. Med. J,
doi:10.1136/bmj.o2690Ishihara, Koketsu, Fukuta, Nada, Reaction of lithium aluminum hydride with elemental selenium: Its application as a selenating reagent into organic molecules, J. Am. Chem. Soc,
doi:10.1021/ja005800oJiang, Zou, Zeng, Zeng, Zhou et al., Crystal structures of main protease (M pro ) mutants of SARS-CoV-2 variants bound to PF-07304814, Mol. Biomed,
doi:10.1186/s43556-023-00134-2Kabinger, Stiller, Schmitzova, Dienemann, Kokic et al., Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis, Nat. Struct. Mol. Biol,
doi:10.1038/s41594-021-00651-0Kamal, Ramadan, Farraj, Bahig, Ezzat, The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review, Saudi Pharm. J,
doi:10.1016/j.jsps.2022.03.002Karniadakis, Mazonakis, Tsioutis, Papadakis, Markaki et al., Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence, Infect. Dis. Rep,
doi:10.3390/idr15060061Kelley, De Moor, Douglas, Renshaw, Traviglia, Monoclonal antibody therapies for COVID-19: Lessons learned and implications for the development of future products, Curr. Opin. Biotechnol,
doi:10.1016/j.copbio.2022.102798Kip, Mccreary, Collins, Minnier, Snyder et al., Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 A Cohort Study, Ann. Intern. Med,
doi:10.7326/M22-1286Kovacs, Kurtan, Varga, Nagy, Panyi et al., remdesivir) formulations inhibit initial membranecoupled events of SARS-CoV-2 infection due to their sulfobutylether-beta-cyclodextrin content, Br. J. Pharmacol,
doi:10.1111/bph.16063Li, Lin, Zhou, Zhong, Zeng et al., Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814, J. Mol. Biol,
doi:10.1016/j.jmb.2022.167706Li, Niu, A commentary on "The socio-economic implications of the coronavirus pandemic (COVID-19): A review, Int. J. Surg,
doi:10.1016/j.ijsu.2021.106048Li, Wang, Tian, Pang, Yang et al., COVID-19 vaccine development: Milestones, lessons and prospects, Signal Transduct. Target. Ther,
doi:10.1038/s41392-022-00996-yLiu, Wu, Huang, Hsu, Chuang et al., Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases, Expert Rev. Anti-Infect. Ther,
doi:10.1080/14787210.2023.2284367Ma, Hu, Townsend, Lagarias, Marty et al., Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors, ACS Pharmacol. Transl. Sci,
doi:10.1021/acsptsci.0c00130Narayanan, Narwal, Majowicz, Varricchio, Toner et al., Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay, Commun. Biol,
doi:10.1038/s42003-022-03090-9Ng, Correia, Seagal, Degoey, Schrimpf et al., Antiviral Drug Discovery for the Treatment of COVID-19 Infections, Viruses,
doi:10.3390/v14050961Niknam, Jafari, Golchin, Danesh Pouya, Nemati et al., Potential therapeutic options for COVID-19: An update on current evidence, Eur. J. Med. Res,
doi:10.1186/s40001-021-00626-3Nocentini, Capasso, Supuran, Perspectives on the design and discovery of alpha-ketoamide inhibitors for the treatment of novel coronavirus: Where do we stand and where do we go?, Expert Opin. Drug Discov,
doi:10.1080/17460441.2022.2052847Pilote, Simard, Drolet, Remdesivir, VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects, J. Cardiovasc. Pharmacol,
doi:10.1097/FJC.0000000000001321Ravaghi, Naidoo, Mataria, Khalil, Hospitals early challenges and interventions combatting COVID-19 in the Eastern Mediterranean Region, PLoS ONE,
doi:10.1371/journal.pone.0268386Ravi, Eerike, Konda, Bisoi, Raj et al., Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review. Monoclon. Antibodies Immunodiagn, Immunother,
doi:10.1089/mab.2022.0036Razali, Subbiah, Budiman, Technical Data of Heterologous Expression and Purification of SARS-CoV-2 Proteases Using Escherichia coli System, Data,
doi:10.3390/data6090099Sacco, Ma, Lagarias, Gao, Townsend et al., Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M pro and cathepsin L, Sci. Adv,
doi:10.1126/sciadv.abe0751Sardar, Abdul-Khaliq, Ingar, Amaidia, Mansour, COVID-19 lockdown: A protective measure or exacerbator of health inequalities? A comparison between the United Kingdom and India.' a commentary on "the socio-economic implications of the coronavirus and COVID-19 pandemic: A review, Int. J. Surg,
doi:10.1016/j.ijsu.2020.09.044Sharun, Tiwari, Dhama, Dhama, Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence, Int. J. Surg,
doi:10.1016/j.ijsu.2020.08.038Tanini, Carradori, Capperucci, Lupori, Zara et al., Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly reverted oxaliplatin-induced neuropathy and enhanced antiproliferative action, Eur. J. Med. Chem,
doi:10.1016/j.ejmech.2021.113793Tanini, Scarpelli, Ermini, Capperucci, Seleno-Michael Reaction of Stable Functionalised Alkyl Selenols: A Versatile Tool for the Synthesis of Acyclic and Cyclic Unsymmetrical Alkyl and Vinyl Selenides, Adv. Synth. Catal,
doi:10.1002/adsc.201900168Tanini, Tiberi, Gellini, Salvi, Capperucci, A Straightforward Access to Stable β-Functionalized Alkyl Selenols, Adv. Synth. Catal,
doi:10.1002/adsc.201800602Thakkar, Agarwal, Ranaweera, Ishiguro, Conda-Sheridan et al., De novo design of a stapled peptide targeting SARS-CoV-2 spike protein receptor-binding domain, RSC Med. Chem,
doi:10.1039/D3MD00222EWang, Yang, Yang, Hou, Tsai et al., Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug, Am. J. Cancer Res
Wynter-Adams, Thomas-Brown, COVID-19 vaccine hesitancy in a developing country: Prevalence, explanatory factors and implications for the future, Public Health,
doi:10.1016/j.puhe.2023.01.031Yadav, Chaudhary, Jain, Chaudhary, Khanra et al., Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19, Cells,
doi:10.3390/cells10040821Yang, Ju, Wang, Jia, Wang et al., Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature, J. Clin. Lab. Anal,
doi:10.1002/jcla.24880Zhang, Lin, Sun, Curth, Drosten et al., Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors, Science,
doi:10.1126/science.abb3405Zhao, Fang, Zhang, Zhang, Zhao et al., Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332, Protein Cell,
doi:10.1007/s13238-021-00883-2{ 'DOI': '10.3390/ijms25020971',
'ISSN': ['1422-0067'],
'URL': 'http://dx.doi.org/10.3390/ijms25020971',
'abstract': '<jats:p>The implementation of innovative approaches is crucial in an ongoing endeavor to '
'mitigate the impact of COVID-19 pandemic. The present study examines the strategic '
'application of the SARS-CoV-2 Main Protease (Mpro) as a prospective instrument in the '
'repertoire to combat the virus. The cloning, expression, and purification of Mpro, which '
'plays a critical role in the viral life cycle, through heterologous expression in Escherichia '
'coli in a completely soluble form produced an active enzyme. The hydrolysis of a specific '
'substrate peptide comprising a six-amino-acid sequence (TSAVLQ) linked to a p-nitroaniline '
'(pNA) fragment together with the use of a fluorogenic substrate allowed us to determine '
'effective inhibitors incorporating selenium moieties, such as benzoselenoates and '
'carbamoselenoates. The new inhibitors revealed their potential to proficiently inhibit Mpro '
'with IC50-s in the low micromolar range. Our study contributes to the development of a new '
'class of protease inhibitors targeting Mpro, ultimately strengthening the antiviral arsenal '
'against COVID-19 and possibly, related coronaviruses.</jats:p>',
'alternative-id': ['ijms25020971'],
'author': [ { 'affiliation': [ { 'name': 'Department of Biology, Agriculture and Food Sciences, National '
'Research Council (CNR), Institute of Biosciences and '
'Bioresources, 80131 Naples, Italy'}],
'family': 'De Luca',
'given': 'Viviana',
'sequence': 'first'},
{ 'ORCID': 'http://orcid.org/0000-0002-1470-7192',
'affiliation': [ { 'name': 'Neurofarba Department, Pharmaceutical and Nutraceutical Section, '
'Laboratory of Molecular Modeling Cheminformatics & QSAR, '
'University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, '
'50019 Florence, Italy'}],
'authenticated-orcid': False,
'family': 'Angeli',
'given': 'Andrea',
'sequence': 'additional'},
{ 'ORCID': 'http://orcid.org/0000-0003-3342-702X',
'affiliation': [ { 'name': 'Neurofarba Department, Pharmaceutical and Nutraceutical Section, '
'Laboratory of Molecular Modeling Cheminformatics & QSAR, '
'University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, '
'50019 Florence, Italy'}],
'authenticated-orcid': False,
'family': 'Nocentini',
'given': 'Alessio',
'sequence': 'additional'},
{ 'ORCID': 'http://orcid.org/0000-0002-9137-2509',
'affiliation': [ { 'name': 'Neurofarba Department, Pharmaceutical and Nutraceutical Section, '
'Laboratory of Molecular Modeling Cheminformatics & QSAR, '
'University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, '
'50019 Florence, Italy'}],
'authenticated-orcid': False,
'family': 'Gratteri',
'given': 'Paola',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Chemistry “Ugo Schiff”, University of Florence, '
'Via Della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, '
'Italy'}],
'family': 'Pratesi',
'given': 'Silvia',
'sequence': 'additional'},
{ 'ORCID': 'http://orcid.org/0000-0001-8930-3566',
'affiliation': [ { 'name': 'Department of Chemistry “Ugo Schiff”, University of Florence, '
'Via Della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, '
'Italy'}],
'authenticated-orcid': False,
'family': 'Tanini',
'given': 'Damiano',
'sequence': 'additional'},
{ 'ORCID': 'http://orcid.org/0000-0002-1842-494X',
'affiliation': [ { 'name': 'Department of Biology, Agriculture and Food Sciences, National '
'Research Council (CNR), Institute of Biosciences and '
'Bioresources, 80131 Naples, Italy'}],
'authenticated-orcid': False,
'family': 'Carginale',
'given': 'Vincenzo',
'sequence': 'additional'},
{ 'affiliation': [ { 'name': 'Department of Chemistry “Ugo Schiff”, University of Florence, '
'Via Della Lastruccia 3-13, Sesto Fiorentino, 50019 Florence, '
'Italy'}],
'family': 'Capperucci',
'given': 'Antonella',
'sequence': 'additional'},
{ 'ORCID': 'http://orcid.org/0000-0003-4262-0323',
'affiliation': [ { 'name': 'Neurofarba Department, Pharmaceutical and Nutraceutical Section, '
'Laboratory of Molecular Modeling Cheminformatics & QSAR, '
'University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, '
'50019 Florence, Italy'}],
'authenticated-orcid': False,
'family': 'Supuran',
'given': 'Claudiu T.',
'sequence': 'additional'},
{ 'ORCID': 'http://orcid.org/0000-0003-3314-2411',
'affiliation': [ { 'name': 'Department of Biology, Agriculture and Food Sciences, National '
'Research Council (CNR), Institute of Biosciences and '
'Bioresources, 80131 Naples, Italy'}],
'authenticated-orcid': False,
'family': 'Capasso',
'given': 'Clemente',
'sequence': 'additional'}],
'container-title': 'International Journal of Molecular Sciences',
'container-title-short': 'IJMS',
'content-domain': {'crossmark-restriction': False, 'domain': []},
'created': {'date-parts': [[2024, 1, 12]], 'date-time': '2024-01-12T12:47:16Z', 'timestamp': 1705063636000},
'deposited': { 'date-parts': [[2024, 1, 12]],
'date-time': '2024-01-12T13:12:11Z',
'timestamp': 1705065131000},
'funder': [{'name': 'Italian National Research Council'}],
'indexed': {'date-parts': [[2024, 1, 13]], 'date-time': '2024-01-13T00:37:52Z', 'timestamp': 1705106272579},
'is-referenced-by-count': 0,
'issue': '2',
'issued': {'date-parts': [[2024, 1, 12]]},
'journal-issue': {'issue': '2', 'published-online': {'date-parts': [[2024, 1]]}},
'language': 'en',
'license': [ { 'URL': 'https://creativecommons.org/licenses/by/4.0/',
'content-version': 'vor',
'delay-in-days': 0,
'start': { 'date-parts': [[2024, 1, 12]],
'date-time': '2024-01-12T00:00:00Z',
'timestamp': 1705017600000}}],
'link': [ { 'URL': 'https://www.mdpi.com/1422-0067/25/2/971/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'member': '1968',
'original-title': [],
'page': '971',
'prefix': '10.3390',
'published': {'date-parts': [[2024, 1, 12]]},
'published-online': {'date-parts': [[2024, 1, 12]]},
'publisher': 'MDPI AG',
'reference': [ { 'DOI': '10.1038/s41579-023-00878-2',
'article-title': 'The evolution of SARS-CoV-2',
'author': 'Markov',
'doi-asserted-by': 'crossref',
'first-page': '361',
'journal-title': 'Nat. Rev. Microbiol.',
'key': 'ref_1',
'volume': '21',
'year': '2023'},
{ 'DOI': '10.1016/j.ijsu.2021.106048',
'article-title': 'A commentary on “The socio-economic implications of the coronavirus '
'pandemic (COVID-19): A review”',
'author': 'Li',
'doi-asserted-by': 'crossref',
'first-page': '106048',
'journal-title': 'Int. J. Surg.',
'key': 'ref_2',
'volume': '95',
'year': '2021'},
{ 'DOI': '10.1016/j.ijsu.2020.09.044',
'article-title': '‘COVID-19 lockdown: A protective measure or exacerbator of health '
'inequalities? A comparison between the United Kingdom and India.’ a '
'commentary on “the socio-economic implications of the coronavirus and '
'COVID-19 pandemic: A review”',
'author': 'Sardar',
'doi-asserted-by': 'crossref',
'first-page': '189',
'journal-title': 'Int. J. Surg.',
'key': 'ref_3',
'volume': '83',
'year': '2020'},
{ 'DOI': '10.1016/j.frl.2021.102245',
'article-title': 'Stock market reactions to COVID-19 lockdown: A global analysis',
'author': 'Scherf',
'doi-asserted-by': 'crossref',
'first-page': '102245',
'journal-title': 'Financ. Res. Lett.',
'key': 'ref_4',
'volume': '45',
'year': '2022'},
{ 'DOI': '10.1016/j.puhip.2020.100061',
'article-title': 'Pfizer: The miracle vaccine for COVID-19?',
'author': 'Badiani',
'doi-asserted-by': 'crossref',
'first-page': '100061',
'journal-title': 'Public Health Pract.',
'key': 'ref_5',
'volume': '1',
'year': '2020'},
{ 'article-title': 'SARS-CoV-2 variant biology: Immune escape, transmission and fitness',
'author': 'Carabelli',
'first-page': '162',
'journal-title': 'Nat. Rev. Microbiol.',
'key': 'ref_6',
'volume': '21',
'year': '2023'},
{ 'DOI': '10.1038/s41392-022-00996-y',
'article-title': 'COVID-19 vaccine development: Milestones, lessons and prospects',
'author': 'Li',
'doi-asserted-by': 'crossref',
'first-page': '146',
'journal-title': 'Signal Transduct. Target. Ther.',
'key': 'ref_7',
'volume': '7',
'year': '2022'},
{ 'DOI': '10.1002/cmdc.202200440',
'article-title': 'Recent Drug Development and Medicinal Chemistry Approaches for the '
'Treatment of SARS-CoV-2 Infection and COVID-19',
'author': 'Ghosh',
'doi-asserted-by': 'crossref',
'first-page': 'e202200440',
'journal-title': 'ChemMedChem',
'key': 'ref_8',
'volume': '17',
'year': '2022'},
{ 'DOI': '10.1097/MCP.0000000000000953',
'article-title': 'Drug treatment of COVID-19 infection',
'author': 'Lui',
'doi-asserted-by': 'crossref',
'first-page': '174',
'journal-title': 'Curr. Opin. Pulm. Med.',
'key': 'ref_9',
'volume': '29',
'year': '2023'},
{ 'DOI': '10.1371/journal.pone.0268386',
'doi-asserted-by': 'crossref',
'key': 'ref_10',
'unstructured': 'Ravaghi, H., Naidoo, V., Mataria, A., and Khalil, M. (2022). Hospitals '
'early challenges and interventions combatting COVID-19 in the Eastern '
'Mediterranean Region. PLoS ONE, 17.'},
{ 'DOI': '10.1016/j.ijsu.2020.08.038',
'article-title': 'Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and '
'preliminary evidence',
'author': 'Sharun',
'doi-asserted-by': 'crossref',
'first-page': '179',
'journal-title': 'Int. J. Surg.',
'key': 'ref_11',
'volume': '82',
'year': '2020'},
{ 'article-title': 'Two Years into the COVID-19 Pandemic: Lessons Learned',
'author': 'Mendes',
'first-page': '1758',
'journal-title': 'ACS Infect. Dis.',
'key': 'ref_12',
'volume': '8',
'year': '2020'},
{ 'DOI': '10.3390/futurepharmacol2040036',
'article-title': 'Selenium-Based Drug Development for Antioxidant and Anticancer Activity',
'author': 'Debnath',
'doi-asserted-by': 'crossref',
'first-page': '595',
'journal-title': 'Future Pharmacol.',
'key': 'ref_13',
'volume': '2',
'year': '2022'},
{ 'DOI': '10.1016/j.drudis.2020.10.014',
'article-title': 'The innovative potential of seleniumcontaining agents for fighting '
'cancer and viral infections',
'author': 'Ali',
'doi-asserted-by': 'crossref',
'first-page': '256',
'journal-title': 'Drug Discov. Today',
'key': 'ref_14',
'volume': '26',
'year': '2021'},
{ 'DOI': '10.1016/j.drudis.2022.03.020',
'article-title': 'Selenium as an emerging versatile player in heterocycles and natural '
'products modification',
'author': 'Hou',
'doi-asserted-by': 'crossref',
'first-page': '2268',
'journal-title': 'Drug Discov. Today',
'key': 'ref_15',
'volume': '27',
'year': '2022'},
{ 'DOI': '10.1002/cmdc.202200085',
'article-title': 'Selenocarbamates As a Prodrug-Based Approach to Carbonic Anhydrase '
'Inhibition',
'author': 'Angeli',
'doi-asserted-by': 'crossref',
'first-page': 'e202200085',
'journal-title': 'ChemMedChem',
'key': 'ref_16',
'volume': '17',
'year': '2022'},
{ 'DOI': '10.1016/j.ejmech.2021.113793',
'article-title': 'Chalcogenides-incorporating carbonic anhydrase inhibitors concomitantly '
'reverted oxaliplatin-induced neuropathy and enhanced antiproliferative '
'action',
'author': 'Tanini',
'doi-asserted-by': 'crossref',
'first-page': '113793',
'journal-title': 'Eur. J. Med. Chem.',
'key': 'ref_17',
'volume': '225',
'year': '2021'},
{ 'DOI': '10.1038/s41586-020-2223-y',
'article-title': 'Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors',
'author': 'Jin',
'doi-asserted-by': 'crossref',
'first-page': '289',
'journal-title': 'Nature',
'key': 'ref_18',
'volume': '582',
'year': '2020'},
{ 'DOI': '10.1021/acsptsci.0c00130',
'article-title': 'Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are '
'Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors',
'author': 'Ma',
'doi-asserted-by': 'crossref',
'first-page': '1265',
'journal-title': 'ACS Pharmacol. Transl. Sci.',
'key': 'ref_19',
'volume': '3',
'year': '2020'},
{ 'DOI': '10.1038/s41467-021-23313-7',
'article-title': 'Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its '
'derivatives',
'author': 'Amporndanai',
'doi-asserted-by': 'crossref',
'first-page': '3061',
'journal-title': 'Nat. Commun.',
'key': 'ref_20',
'volume': '12',
'year': '2021'},
{ 'DOI': '10.1111/bph.16063',
'article-title': 'Veklury(R) (remdesivir) formulations inhibit initial membrane-coupled '
'events of SARS-CoV-2 infection due to their '
'sulfobutylether-beta-cyclodextrin content',
'author': 'Kovacs',
'doi-asserted-by': 'crossref',
'first-page': '2064',
'journal-title': 'Br. J. Pharmacol.',
'key': 'ref_21',
'volume': '180',
'year': '2023'},
{ 'DOI': '10.1097/FJC.0000000000001321',
'article-title': 'Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In '
'Vivo Cardiac Electrophysiological Effects',
'author': 'Pilote',
'doi-asserted-by': 'crossref',
'first-page': '616',
'journal-title': 'J. Cardiovasc. Pharmacol.',
'key': 'ref_22',
'volume': '80',
'year': '2022'},
{ 'DOI': '10.1016/j.copbio.2022.102798',
'article-title': 'Monoclonal antibody therapies for COVID-19: Lessons learned and '
'implications for the development of future products',
'author': 'Kelley',
'doi-asserted-by': 'crossref',
'first-page': '102798',
'journal-title': 'Curr. Opin. Biotechnol.',
'key': 'ref_23',
'volume': '78',
'year': '2022'},
{ 'DOI': '10.1089/mab.2022.0036',
'article-title': 'Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An '
'Updated Review',
'author': 'Ravi',
'doi-asserted-by': 'crossref',
'first-page': '77',
'journal-title': 'Monoclon. Antibodies Immunodiagn. Immunother.',
'key': 'ref_24',
'volume': '42',
'year': '2023'},
{ 'article-title': 'Nasally Administered Monoclonal Antibody for COVID-19',
'author': 'Harris',
'first-page': '1142',
'journal-title': 'JAMA-J. Am. Med. Assoc.',
'key': 'ref_25',
'volume': '329',
'year': '2023'},
{ 'DOI': '10.7326/M22-1286',
'article-title': 'Evolving Real-World Effectiveness of Monoclonal Antibodies for '
'Treatment of COVID-19 A Cohort Study',
'author': 'Kip',
'doi-asserted-by': 'crossref',
'first-page': '496',
'journal-title': 'Ann. Intern. Med.',
'key': 'ref_26',
'volume': '176',
'year': '2023'},
{ 'DOI': '10.1016/j.puhe.2023.01.031',
'article-title': 'COVID-19 vaccine hesitancy in a developing country: Prevalence, '
'explanatory factors and implications for the future',
'doi-asserted-by': 'crossref',
'first-page': '146',
'journal-title': 'Public Health',
'key': 'ref_27',
'volume': '217',
'year': '2023'},
{ 'DOI': '10.1136/bmj.o2690',
'article-title': 'COVID-19: Evusheld protects the most vulnerable patients, analysis '
'shows',
'author': 'Iacobucci',
'doi-asserted-by': 'crossref',
'first-page': 'o2690',
'journal-title': 'BMJ-Br. Med. J.',
'key': 'ref_28',
'volume': '379',
'year': '2022'},
{ 'DOI': '10.1186/s40001-021-00626-3',
'article-title': 'Potential therapeutic options for COVID-19: An update on current '
'evidence',
'author': 'Niknam',
'doi-asserted-by': 'crossref',
'first-page': '6',
'journal-title': 'Eur. J. Med. Res.',
'key': 'ref_29',
'volume': '27',
'year': '2022'},
{ 'DOI': '10.3390/v14050961',
'doi-asserted-by': 'crossref',
'key': 'ref_30',
'unstructured': 'Ng, T.I., Correia, I., Seagal, J., DeGoey, D.A., Schrimpf, M.R., Hardee, '
'D.J., Noey, E.L., and Kati, W.M. (2022). Antiviral Drug Discovery for '
'the Treatment of COVID-19 Infections. Viruses, 14.'},
{ 'DOI': '10.1038/s41594-021-00651-0',
'article-title': 'Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis',
'author': 'Kabinger',
'doi-asserted-by': 'crossref',
'first-page': '740',
'journal-title': 'Nat. Struct. Mol. Biol.',
'key': 'ref_31',
'volume': '28',
'year': '2021'},
{ 'DOI': '10.1016/j.jsps.2022.03.002',
'article-title': 'The pill of recovery; Molnupiravir for treatment of COVID-19 patients; '
'a systematic review',
'author': 'Kamal',
'doi-asserted-by': 'crossref',
'first-page': '508',
'journal-title': 'Saudi Pharm. J.',
'key': 'ref_32',
'volume': '30',
'year': '2022'},
{ 'article-title': 'Nirmatrelvir/ritonavir (Paxlovid(R)), a treatment for COVID-19',
'author': 'Buxeraud',
'first-page': '10',
'journal-title': 'Actual. Pharm.',
'key': 'ref_33',
'volume': '61',
'year': '2022'},
{ 'DOI': '10.1002/jcla.24880',
'article-title': 'Proxalutamide for the treatment of COVID-19 rebound following Paxlovid '
'treatment: Report of four cases and review of the literature',
'author': 'Yang',
'doi-asserted-by': 'crossref',
'first-page': 'e24880',
'journal-title': 'J. Clin. Lab. Anal.',
'key': 'ref_34',
'volume': '37',
'year': '2023'},
{ 'DOI': '10.1007/s43440-022-00425-5',
'article-title': 'Recent review of COVID-19 management: Diagnosis, treatment and '
'vaccination',
'author': 'Chavda',
'doi-asserted-by': 'crossref',
'first-page': '1120',
'journal-title': 'Pharmacol. Rep.',
'key': 'ref_35',
'volume': '74',
'year': '2022'},
{ 'DOI': '10.1016/j.biopha.2023.114367',
'doi-asserted-by': 'crossref',
'key': 'ref_36',
'unstructured': 'Hashemian, S.M.R., Sheida, A., Taghizadieh, M., Memar, M.Y., Hamblin, '
'M.R., Bannazadeh Baghi, H., Sadri Nahand, J., Asemi, Z., and Mirzaei, H. '
'(2023). Paxlovid (Nirmatrelvir/Ritonavir): A new approach to COVID-19 '
'therapy?. Biomed. Pharmacother., 162.'},
{ 'DOI': '10.1021/acsomega.2c03881',
'article-title': 'Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: A '
'Very Promising Potential Universal Broad-Spectrum Antiviral at the '
'Therapeutic Frontline of Coronavirus Species',
'author': 'Eltayb',
'doi-asserted-by': 'crossref',
'first-page': '5234',
'journal-title': 'ACS Omega',
'key': 'ref_37',
'volume': '8',
'year': '2023'},
{ 'DOI': '10.3390/cells10040821',
'doi-asserted-by': 'crossref',
'key': 'ref_38',
'unstructured': 'Yadav, R., Chaudhary, J.K., Jain, N., Chaudhary, P.K., Khanra, S., '
'Dhamija, P., Sharma, A., Kumar, A., and Handu, S. (2021). Role of '
'Structural and Non-Structural Proteins and Therapeutic Targets of '
'SARS-CoV-2 for COVID-19. Cells, 10.'},
{ 'DOI': '10.1080/13543776.2020.1760838',
'article-title': 'A deadly spillover: SARS-CoV-2 outbreak',
'author': 'Mori',
'doi-asserted-by': 'crossref',
'first-page': '481',
'journal-title': 'Expert Opin. Ther. Pat.',
'key': 'ref_39',
'volume': '30',
'year': '2020'},
{ 'DOI': '10.1080/13543776.2021.1857726',
'article-title': 'Protease inhibitors targeting the main protease and papain-like '
'protease of coronaviruses',
'author': 'Capasso',
'doi-asserted-by': 'crossref',
'first-page': '309',
'journal-title': 'Expert Opin. Ther. Pat.',
'key': 'ref_40',
'volume': '31',
'year': '2021'},
{ 'DOI': '10.1080/14756366.2021.1924165',
'article-title': 'Is carbonic anhydrase inhibition useful as a complementary therapy of '
'COVID-19 infection?',
'author': 'Deniz',
'doi-asserted-by': 'crossref',
'first-page': '1230',
'journal-title': 'J. Enzym. Inhib. Med. Chem.',
'key': 'ref_41',
'volume': '36',
'year': '2021'},
{ 'DOI': '10.3390/biom11040607',
'doi-asserted-by': 'crossref',
'key': 'ref_42',
'unstructured': 'Citarella, A., Scala, A., Piperno, A., and Micale, N. (2021). SARS-CoV-2 '
'Mpro: A Potential Target for Peptidomimetics and Small-Molecule '
'Inhibitors. Biomolecules, 11.'},
{ 'DOI': '10.7554/eLife.77433',
'article-title': 'Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights '
'into viral resistance mechanisms',
'author': 'Flynn',
'doi-asserted-by': 'crossref',
'first-page': 'e77433',
'journal-title': 'eLife',
'key': 'ref_43',
'volume': '11',
'year': '2022'},
{ 'article-title': 'The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging '
'therapies for COVID-19',
'author': 'Hu',
'first-page': 'e151',
'journal-title': 'MedComm (2020)',
'key': 'ref_44',
'volume': '3',
'year': '2022'},
{ 'DOI': '10.3389/fchem.2021.622898',
'article-title': 'Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main '
'Protease',
'author': 'Mengist',
'doi-asserted-by': 'crossref',
'first-page': '622898',
'journal-title': 'Front. Chem.',
'key': 'ref_45',
'volume': '9',
'year': '2021'},
{ 'DOI': '10.1016/j.pep.2011.08.005',
'article-title': 'An overview of enzymatic reagents for the removal of affinity tags',
'author': 'Waugh',
'doi-asserted-by': 'crossref',
'first-page': '283',
'journal-title': 'Protein Expr. Purif.',
'key': 'ref_46',
'volume': '80',
'year': '2011'},
{ 'DOI': '10.1126/science.abb3405',
'article-title': 'Crystal structure of SARS-CoV-2 main protease provides a basis for '
'design of improved alpha-ketoamide inhibitors',
'author': 'Zhang',
'doi-asserted-by': 'crossref',
'first-page': '409',
'journal-title': 'Science',
'key': 'ref_47',
'volume': '368',
'year': '2020'},
{ 'DOI': '10.3390/data6090099',
'doi-asserted-by': 'crossref',
'key': 'ref_48',
'unstructured': 'Razali, R., Subbiah, V.K., and Budiman, C. (2021). Technical Data of '
'Heterologous Expression and Purification of SARS-CoV-2 Proteases Using '
'Escherichia coli System. Data, 6.'},
{ 'DOI': '10.1126/sciadv.abe0751',
'article-title': 'Structure and inhibition of the SARS-CoV-2 main protease reveal '
'strategy for developing dual inhibitors against Mpro and cathepsin L',
'author': 'Sacco',
'doi-asserted-by': 'crossref',
'first-page': 'eabe0751',
'journal-title': 'Sci. Adv.',
'key': 'ref_49',
'volume': '6',
'year': '2020'},
{ 'DOI': '10.1016/j.compbiomed.2020.104117',
'article-title': 'Evaluation of acridinedione analogs as potential SARS-CoV-2 main '
'protease inhibitors and their comparison with repurposed anti-viral '
'drugs',
'author': 'Bhardwaj',
'doi-asserted-by': 'crossref',
'first-page': '104117',
'journal-title': 'Comput. Biol. Med.',
'key': 'ref_50',
'volume': '128',
'year': '2021'},
{ 'DOI': '10.1016/j.bmcl.2020.127377',
'article-title': 'The SARS-CoV-2 main protease as drug target',
'author': 'Ullrich',
'doi-asserted-by': 'crossref',
'first-page': '127377',
'journal-title': 'Bioorganic Med. Chem. Lett.',
'key': 'ref_51',
'volume': '30',
'year': '2020'},
{ 'DOI': '10.1007/s13238-021-00883-2',
'article-title': 'Crystal structure of SARS-CoV-2 main protease in complex with protease '
'inhibitor PF-07321332',
'author': 'Zhao',
'doi-asserted-by': 'crossref',
'first-page': '689',
'journal-title': 'Protein Cell',
'key': 'ref_52',
'volume': '13',
'year': '2022'},
{ 'DOI': '10.3389/fphar.2022.1035969',
'article-title': 'Review of preclinical data of PF-07304814 and its active metabolite '
'derivatives against SARS-CoV-2 infection',
'author': 'Chen',
'doi-asserted-by': 'crossref',
'first-page': '1035969',
'journal-title': 'Front. Pharmacol.',
'key': 'ref_53',
'volume': '13',
'year': '2022'},
{ 'DOI': '10.1186/s43556-023-00134-2',
'article-title': 'Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 '
'variants bound to PF-07304814',
'author': 'Jiang',
'doi-asserted-by': 'crossref',
'first-page': '23',
'journal-title': 'Mol. Biomed.',
'key': 'ref_54',
'volume': '4',
'year': '2023'},
{ 'DOI': '10.1016/j.jmb.2022.167706',
'article-title': 'Structural Basis of Main Proteases of Coronavirus Bound to Drug '
'Candidate PF-07304814',
'author': 'Li',
'doi-asserted-by': 'crossref',
'first-page': '167706',
'journal-title': 'J. Mol. Biol.',
'key': 'ref_55',
'volume': '434',
'year': '2022'},
{ 'DOI': '10.3390/idr15060061',
'article-title': 'Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of '
'COVID-19: A Literature Review with a Focus on Real-World Evidence',
'author': 'Karniadakis',
'doi-asserted-by': 'crossref',
'first-page': '662',
'journal-title': 'Infect. Dis. Rep.',
'key': 'ref_56',
'volume': '15',
'year': '2023'},
{ 'DOI': '10.1080/14787210.2023.2284367',
'doi-asserted-by': 'crossref',
'key': 'ref_57',
'unstructured': 'Liu, T.H., Wu, J.Y., Huang, P.Y., Hsu, W.H., Chuang, M.H., Tsai, Y.W., '
'Lai, C.C., and Huang, C.Y. (2023). Clinical efficacy of nirmatrelvir '
'plus ritonavir in patients with COVID-19 and preexisting cardiovascular '
'diseases. Expert Rev. Anti-Infect. Ther., 1–8.'},
{ 'DOI': '10.1002/adsc.202101147',
'article-title': 'Synthesis and Applications of Organic Selenols',
'author': 'Tanini',
'doi-asserted-by': 'crossref',
'first-page': '5360',
'journal-title': 'Adv. Synth. Catal.',
'key': 'ref_58',
'volume': '363',
'year': '2021'},
{ 'DOI': '10.1002/adsc.201900168',
'article-title': 'Seleno-Michael Reaction of Stable Functionalised Alkyl Selenols: A '
'Versatile Tool for the Synthesis of Acyclic and Cyclic Unsymmetrical '
'Alkyl and Vinyl Selenides',
'author': 'Tanini',
'doi-asserted-by': 'crossref',
'first-page': '2337',
'journal-title': 'Adv. Synth. Catal.',
'key': 'ref_59',
'volume': '361',
'year': '2019'},
{ 'DOI': '10.1002/adsc.201800602',
'article-title': 'A Straightforward Access to Stable β-Functionalized Alkyl Selenols',
'author': 'Tanini',
'doi-asserted-by': 'crossref',
'first-page': '3367',
'journal-title': 'Adv. Synth. Catal.',
'key': 'ref_60',
'volume': '360',
'year': '2018'},
{ 'DOI': '10.1039/C8CC08562E',
'article-title': 'Selenols: A new class of carbonic anhydrase inhibitors',
'author': 'Angeli',
'doi-asserted-by': 'crossref',
'first-page': '648',
'journal-title': 'Chem. Commun.',
'key': 'ref_61',
'volume': '55',
'year': '2019'},
{ 'DOI': '10.1039/D0CC00995D',
'article-title': 'Selenolesterase enzyme activity of carbonic anhydrases',
'author': 'Angeli',
'doi-asserted-by': 'crossref',
'first-page': '4444',
'journal-title': 'Chem. Commun.',
'key': 'ref_62',
'volume': '56',
'year': '2020'},
{ 'DOI': '10.1002/adsc.202100611',
'article-title': 'Click Reaction of Selenols with Isocyanates: Rapid Access to '
'Selenocarbamates as Peroxide-Switchable Reservoir of '
'Thiol-peroxidase-Like Catalysts',
'author': 'Capperucci',
'doi-asserted-by': 'crossref',
'first-page': '4256',
'journal-title': 'Adv. Synth. Catal.',
'key': 'ref_63',
'volume': '363',
'year': '2021'},
{ 'DOI': '10.1021/ja005800o',
'article-title': 'Reaction of lithium aluminum hydride with elemental selenium: Its '
'application as a selenating reagent into organic molecules',
'author': 'Ishihara',
'doi-asserted-by': 'crossref',
'first-page': '8408',
'journal-title': 'J. Am. Chem. Soc.',
'key': 'ref_64',
'volume': '123',
'year': '2001'},
{ 'DOI': '10.1126/science.abd9909',
'article-title': 'De novo design of picomolar SARS-CoV-2 miniprotein inhibitors',
'author': 'Cao',
'doi-asserted-by': 'crossref',
'first-page': '426',
'journal-title': 'Science',
'key': 'ref_65',
'volume': '370',
'year': '2020'},
{ 'DOI': '10.1039/D3MD00222E',
'article-title': 'De novo design of a stapled peptide targeting SARS-CoV-2 spike protein '
'receptor-binding domain',
'author': 'Thakkar',
'doi-asserted-by': 'crossref',
'first-page': '1722',
'journal-title': 'RSC Med. Chem.',
'key': 'ref_66',
'volume': '14',
'year': '2023'},
{ 'DOI': '10.1021/acs.jmedchem.0c01063',
'article-title': 'Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL '
'Proteases for the Potential Therapeutic Treatment of COVID-19',
'author': 'Hoffman',
'doi-asserted-by': 'crossref',
'first-page': '12725',
'journal-title': 'J. Med. Chem.',
'key': 'ref_67',
'volume': '63',
'year': '2020'},
{ 'DOI': '10.1038/s42003-022-03090-9',
'article-title': 'Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using '
'in-cell-protease assay',
'author': 'Narayanan',
'doi-asserted-by': 'crossref',
'first-page': '169',
'journal-title': 'Commun. Biol.',
'key': 'ref_68',
'volume': '5',
'year': '2022'},
{ 'article-title': 'Structural basis of SARS-CoV-2 main protease inhibition by a '
'broad-spectrum anti-coronaviral drug',
'author': 'Wang',
'first-page': '2535',
'journal-title': 'Am. J. Cancer Res.',
'key': 'ref_69',
'volume': '10',
'year': '2020'},
{ 'key': 'ref_70',
'unstructured': 'Schrödinger Suite Release 2022-4 (2022). (a) Maestro v.13.2; (b) Prime, '
'v.5.5; (c) Epik, v.6.0; (d) Impact, v.9.5; (e) Macromodel v.13.6. (f) '
'Glide, v.9.5, Schrödinger, LLC.'},
{ 'DOI': '10.1080/17460441.2022.2052847',
'article-title': 'Perspectives on the design and discovery of alpha-ketoamide inhibitors '
'for the treatment of novel coronavirus: Where do we stand and where do '
'we go?',
'author': 'Nocentini',
'doi-asserted-by': 'crossref',
'first-page': '547',
'journal-title': 'Expert Opin. Drug Discov.',
'key': 'ref_71',
'volume': '17',
'year': '2022'},
{ 'DOI': '10.1080/14756366.2023.2234665',
'article-title': 'Identification of sulphonamide-tethered N-((triazol-4-yl)methyl)isatin '
'derivatives as inhibitors of SARS-CoV-2 main protease',
'author': 'ElNaggar',
'doi-asserted-by': 'crossref',
'first-page': '2234665',
'journal-title': 'J. Enzym. Inhib. Med. Chem.',
'key': 'ref_72',
'volume': '38',
'year': '2023'}],
'reference-count': 72,
'references-count': 72,
'relation': {},
'resource': {'primary': {'URL': 'https://www.mdpi.com/1422-0067/25/2/971'}},
'score': 1,
'short-title': [],
'source': 'Crossref',
'subject': [ 'Inorganic Chemistry',
'Organic Chemistry',
'Physical and Theoretical Chemistry',
'Computer Science Applications',
'Spectroscopy',
'Molecular Biology',
'General Medicine',
'Catalysis'],
'subtitle': [],
'title': 'Leveraging SARS-CoV-2 Main Protease (Mpro) for COVID-19 Mitigation with Selenium-Based '
'Inhibitors',
'type': 'journal-article',
'volume': '25'}
